[EN] INHIBITORS OF HCV NS5A<br/>[FR] INHIBITEURS DE NS5A DU VHC
申请人:PRESIDIO PHARMACEUTICALS INC
公开号:WO2011149856A1
公开(公告)日:2011-12-01
Provided herein are compounds, pharmaceutical compositions and combination therapies for inhibition of hepatitis C.
本文提供了一些化合物、药物组合以及联合治疗方案,用于抑制丙型肝炎。
INHIBITORS OF HCV NS5A
申请人:Zhong Min
公开号:US20120122864A1
公开(公告)日:2012-05-17
Provided herein are compounds, pharmaceutical compositions and combination therapies for inhibition of hepatitis C.
本文提供了用于抑制丙型肝炎的化合物、药物组合物和联合治疗方案。
Bower et al., Journal of the Chemical Society, 1950, p. 3341,3343
作者:Bower et al.
DOI:——
日期:——
A series of quinoline analogues as potent inhibitors of C. albicans prolyl tRNA synthetase
作者:Xiang Y. Yu、Jason M. Hill、Guixue Yu、Yifeng Yang、Arthur F. Kluge、Dennis Keith、John Finn、Paul Gallant、Jared Silverman、Audrey Lim
DOI:10.1016/s0960-894x(00)00697-1
日期:2001.2
A series of quinoline inhibitors of C. albicans prolyl tRNA synthetase was identified. The most potent analogue, 2-(4-bromo-phenyl)-6-chloro-8-methyl-4-quinolinecarboxylic acid, showed IC50 = 5 nM (Ca. ProRS) with high selectivity over the human enzyme. (C) 2001 Elsevier Science Ltd. All rights reserved.
[EN] INHIBITORS OF HCV NS5A<br/>[FR] INHIBITEURS DE LA PROTÉINE NS5A DU VHC